Abutaleb, Nader S.Seleem, Mohamed N.2021-08-182021-08-182021-03-292045-232210.1038/s41598-021-86595-3 (PII)http://hdl.handle.net/10919/104672Clostridioides difficile infections (CDIs) are an urgent public health threat worldwide and are a leading cause of morbidity and mortality in healthcare settings. The increasing incidence and severity of infections combined with the scarcity of effective anti-CDI agents has made treatment of CDI very challenging. Therefore, development of new, effective anticlostridial agents remains a high priority. The current study investigated the in vivo efficacy of auranofin in a CDI hamster model. All hamsters treated with auranofin (5 mg/kg) survived a lethal challenge with C. difficile. Furthermore, auranofin (5 mg/kg) was as effective as vancomycin, the drug of choice for treatment of CDIs, against relapsing CDI. Furthermore, auranofin (5 mg/kg) generated a 3.15-log10 reduction (99.97%) in C. difficile count in the cecal contents of hamsters. These results indicate that auranofin warrants further investigation as a new agent to replenish the pipeline of anti-CDI therapeutics.7 page(s)application/pdfenCreative Commons Attribution 4.0 InternationalTREATMENT FAILURE1ST RECURRENCEFIDAXOMICINDIARRHEAMETRONIDAZOLEVANCOMYCINAGENTEPIDEMIOLOGYGUIDELINESRESISTANCEIn vivo efficacy of auranofin in a hamster model of Clostridioides difficile infectionArticle - Refereed2021-08-18Scientific Reportshttps://doi.org/10.1038/s41598-021-86595-3111Seleem, Mohamed [0000-0003-0939-0458]33782498 (pubmed)2045-2322